Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia

European Journal of Haematology

Volumn 91, Issue 3, 2013, Pages 228-235

  Tarkun, Pinar ^a   Mehtap, Ozgur ^a   Atesoǧlu, Elif B ^a   Geduk, Ayfer ^a   Musul, Mahmut M ^a   Hacihanefioglu, Abdullah ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Essential thrombocythemia; Growth differentiation factor 15; Hepcidin; Polycythemia vera

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROID CELL; ERYTHROPOIESIS; FEMALE; GENE; GENE MUTATION; HUMAN; JAK2 GENE; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ESSENTIAL THROMBOCYTHEMIA; GROWTH DIFFERENTIATION FACTOR-15; HEPCIDIN; POLYCYTHEMIA VERA;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDINS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84881661907     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12150     Document Type: Article

References (29)

1. Hoffman R, Baker KR, Prchal JT. The polycthemias. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology Basic Principles and Practice, 4th ed. Philadelphia, PA: Elsevier Churchill Livingstone Press; 2005: 1209-45.
2. Fruchtman SM, Hoffman R. Essential thrombocythemia. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology Basic Principles and Practice, 4th ed. Philadelphia, PA: Elsevier Churchill Livingstone Press; 2005:1277-96.
3. Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology 2006;1:233-9.
4. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573-82.
5. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009;122:78-86.
6. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology 2008;1:151-8.
7. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted proteins biomarkers over expressed in cancer tissue and serum. Proc Natl Acad Sci 2003;100:3410-5.
8. Eling TE, Baek SJ, Shim M, Lee CH. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006;39:649-55.
9. Whitman M. Smads and early developmental signaling by the TGF beta superfamily. Genes Dev 1998;12:2445-62.
10. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF 15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101.
11. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010;17:184-90.
12. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;30:937-51.
13. Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, Rachmilewitz EA. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 2008;142:668-80.
14. Kwapisz J, Zekanowska E, Jasiniewska J. Decreased serum prohepcidin concentration in patients with polycythemia vera. J Zhejiang Univ Sci B 2009;10:791-5.
15. Frazer DM, Anderson GJ. Hepcidin compared with prohepcidin: an absorbing story. Am J Clin Nutr 2009;89:475-6.
16. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis 2011;47:232-4.
17. Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, Swinkels DW, Tanno T, Miller JL. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008;112:5241-4.
18. Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 2008;93:1550-4.
19. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505-8.
20. Mast AE, Foster TM, Pinder HL, Beczkiewicz CA, Bellissimo DB, Murphy AT, Kovacevic S, Wroblewski VJ, Witcher DR. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008;48:2197-204.
21. Frazer DM, Wilkins SJ, Darshan D, Badrick AC, McLaren GD, Anderson GJ. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression. Br J Haematol 2012;157:615-26.
22. Bock O, Höftmann J, Theophile K, Hussein K, Wiese B, Schlué J, Kreipe H. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol 2008;172:951-60.
23. Truska J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci 2006;103:10289-93.
24. Saltzman A, Stone M, Franks C, Searfoss G, Munro R, Jaye M, Ivashchenko Y. Cloning and characterization of human JAK-2 kinase: high mRNA expression in immune cells and muscle tissue. Biochem Biophys Res Commun 1998;246:627-33.
25. Florensa L, Bellosillo B, Besses C, Puigdecanet E, Espinet B, Pérez-Vila E, Longarón R, Vilà RM, Solé F, Serrano S. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients. Leukemia 2006;20:1903-5.
26. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:227-36.
27. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
28. Domenico ID, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. PNAS 2009;106:3800-5.
29. Ross SL, Tran L, Winters A, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab 2012;15:905-17.